From: Iron Metabolism: An Emerging Therapeutic Target in Critical Illness
Study, year [ref], number (n) of patients | Population | Intervention | Outcomes |
---|---|---|---|
Kim, 2017 (FAIRY trial) [48] n = 454 | Anemia post-radical gastrectomy | 500–1000 mg i.v. FCM | Significantly more Hb responders No significant differences in QoL |
Johansson, 2015 (PROTECT trial) [49] n = 60 | Non-anemic patients undergoing cardiac surgery | 100 mg i.v. iron isomaltoside | More non-anemic patients in i.v. iron group Higher Hb 1 month postoperative in i.v. iron group |
Bernabeu-Wittel, 2016 [50] n = 306 | Hip fracture surgery | 1 g i.v. FCM+  40,000 IU s.c. EPO | Higher Hb at discharge and 60-days post-discharge No significant differences in ABT, mortality, HRQoL, adverse events. |
Froessler, 2016 [51] n = 72 | Abdominal surgery with IDA | 500–1000 mg i.v. FCM | Reduced ABT Improved preoperative Hb Improved postoperative Hb Reduced LOS |
Intravenous iron for Treatment of Anemia before Cardiac Surgery (ITACS; ClincialTrials.gov Identifier: NCT02632760) | Anemic patients before elective cardiac surgery | 1 g i.v. FCM (or similar product) | Primary outcome: Number of days alive and out of hospital from surgery to 30 days post-surgery |
Preoperative Intravenous Iron to Treat Anemia in Major Surgery (PREVENTT; ClinicalTrials.gov Identifier: NCT01692418) | Anemic patients before major open abdominal surgery | 1 g i.v. FCM | Primary outcome: ABT requirement |
Intravenous Iron, Functional Recovery and Delirium in Patients with Hip Fracture (FEDEREF; EudraCT: 2014–001923-53) | Hip fracture patients | 200 mg iron sucrose on days 1, 3 and 5 from admission | Primary outcome: Functional variables, including ability to perform activities of daily living and walking. Cognitive variables, including cognitive status and incidence of delirium ABT requirement |